Recon: Embattled Theranos to Finally Shut Down; NICE Okays Novartis' Kymriah After Price Drop

• Blood-Testing Firm Theranos to Dissolve (WSJ) (CNBC) (Financial Times)
• Report: Hospitals mark up drugs by 500% (Axios)
• Insurance tactic drags down U.S. drug prices in second quarter: analyst (Reuters)
• Agios names former Celgene executive Jacqualyn Fouse as next CEO (Reuters) (Forbes)
• Scientists Are Retooling Bacteria to Cure Disease (NYTimes)
• Government Pharma Investigations Target Pricing, Opioids, Trade Practices (Pink Sheet-$)
• IPO: A Go-Go Or A No-No? (LifeSciVC)
• The Amazon-Berkshire-JPM health venture led by Atul Gawande has a COO: Jack Stoddard (CNBC) (BioCentury)
• Is mistrust of ‘big pharma’ enough to help unseat a Democratic stalwart in Congress? (STAT)
• Inappropriate ‘interchangeability’ requirement for biosimilars will cost the US billions (STAT)
• The Senate can change the course of the opioid crisis. Here are 50 ways it can do that (STAT)
• Rudy Giuliani’s Consulting Firm Had Hand In Halting Florida’s Opioid Investigation (KHN)
• CDER Exclusivity Board: Barium is Not an NCE Eligible for 5-Year Exclusivity (FDA Law Blog)

• Gene therapy breakthrough wins world's largest vision award (Reuters)
• Pfizer says Brexit will cost the company $100 million (Pharmafile)
• New report re-ignites fresh buzz that Bayer is prepping an R&D overhaul and job cuts (Endpoints)
• Boost for 'made in China' medicine as Chi-Med wins key approval (Reuters) (STAT)
• After dropping the price, Novartis wins U.K. coverage for its CAR-T drug to treat childhood leukemia (STAT) (BioCentury)
• Merck gets partial thumbs-down on Keytruda in lymphoma from NICE cost-effectiveness watchdogs (Fierce)
• Sanofi reaps first fruit of Ablynx buyout with a European OK for its lead rare disease drug (Endpoints)
• Europe wide policy could boost generics market, study suggests (Pharmafile)
• Bayer forecasts lower earnings on Monsanto delays (Financial Times)
• Vertex Finalizes Orkambi Deal With Australia (BioCentury)
• ProQR drug for rare childhood blindness succeeds in early trial (Reuters)
• EC Approves Puma's Nerlynx As Adjuvant For Breast Cancer (Biocentury)
• Novo, Oxford Uni set to launch diabetes alliance and research labs (PharmaTimes)
• BioMarin investing $43M in fill-finish line at plant in Ireland (Fierce)

• Make The ‘Purple Book’ More Orange, US FDA Told At Biosimilars Hearing (Pink Sheet-$)
• Novo Nordisk Grabs Shark Antibody-Based CNS Delivery Technology From Ossianix (SCRIP-$)
• Pediatrics group encourages parents to steer clear of popular FluMist in favor of shots (STAT)
• Struggling MannKind sees shares rocket up on $105M-plus alliance with United on inhaled treprostinil (Endpoints)
• Radius Health hires oncology-focused CMO as it moves into breast cancer trials (Fierce)
• Sanofi diabetes VP jumps to NYC metabolic disease startup Applied Therapeutics (Fierce)
• Immunotherapy Offers Hope For Some Men With Aggressive Prostate Cancer (Forbes)
• Industry Groups Seek Clarity On FDA's Draft Waiver Guidance Under DSCSA (Pink Sheet-$)
• A 'More Radical Idea': Set Expiration Dates For Priority Review Vouchers (Pink Sheet-$)
• Redmile, GV power exosome specialist Evox to £36M round (Fierce)
• Why Big Pharma Cheers Rahm Emanuel's Exit As Chicago's Mayor (Forbes)
• The high-roller club in biopharma: Who’s paying top-dollar for upfronts? And who are the busiest players at the deal table? (Endpoints)
• FDA Hits Malaysian OTC Manufacturer for Multiple Deficiencies (FDANews-$)
• All study participants have a right to know their own results. My lab has been doing that for years (STAT)
• US FDA marks Lupin’s ‘sartans’ safe, but still issues one observation (InPharmaTechnologist)
• Esketamine closer to shaking up depression market (PharmaLetter-$)
• Bach to Chair MEDCAC (Biocentury)
• Eiger to Seek FDA Approval Of Progeria Therapy (Biocentury)
• Another C-Suite Departure at Immunocore (Biocentury)
• Pfizer Prices $5,000,000,000 Debt Offering (Press)

• Merck's Keytruda threatens Pfizer, Merck KGaA's Bavencio with Merkel cell 'priority' tag (Fierce) (Press)
• BioCryst says oral drug works for HAE attacks (Fierce)
• EyeGate’s anti-inflammatory eye drug and electric delivery device fail phase 3 trial (Fierce)
• Abivax posts ulcerative colitis data, commits to phase 2b (Fierce)
• Lysogene Announces FDA approval of IND Application to Initiate Phase 2-3 Clinical Trial in MPS IIIA (Press)
• Horizon Pharma plc Completes Enrollment of Confirmatory Phase 3 Trial of Teprotumumab Ahead of Schedule (Press)
• Mati Therapeutics Interim Phase II Nepafenac Clinical Trial Results Signal Significant Post-op Pain Reduction in Cataract Surgery Patients (Press)

• Should Medtronic’s return to the standalone continuous glucose monitoring market worry competitors? (MedCity)
• Vyaire Medical, Inc. Recalls Tri-Flo Subglottic Suction System Due to Risk of Device Breakage (FDA)
• Philips inks agreement with Air Force for patient monitoring tech (MedCity)
• TAVR Maturity Not Over the Hump in U.S. (Medpage)
• A Rival to the Renal Denervation Therapy Procedure? (MDDI)
• Biodesix Makes the Case for VeriStrat Through New Study (MDDI)
• MicroPort’s drug-eluting stent performs well in European study (Drug Delivery)
• Nonradioactive Breast Cancer Marking Platform Gains Second Nod from FDA (MDDI)

• A New Lawsuit Threatens Obamacare. Here’s What’s at Stake and What to Expect in Oral Arguments (NYTimes)
• Medicaid To Introduce Value-Based Drug Pricing (Forbes) (Pink Sheet-$)
• Court Can't Block Nonfinal Compounding Policy, FDA Says (Law360-$)
• Sanctions For An MDL Bellwether Plaintiff’s Discovery Conduct (Drug & Device Law)
• Generics Cos. Urge Fed. Circ. To Upend Depomed Patent Win (Law360-$)
• Teva Worker's Discrimination Suit Stays Alive In Pa. (Law360-$)
• Tribe Can't Fault Generics Cos. For Opioid Crisis, Court Told (Law360-$)

• FDA Advisory Committee Calendar

• EMA Clarifies Role Of And Need For Data Monitoring Committees (Pink Sheet-$)
• Medicines: licensing time-based performance measures (MHRA)
• MHRA phase I accreditation scheme (MHRA)
• Number of UK trial contracts collapses ahead of Brexit (PharmaLetter-$)
• Russia approves new state strategy for pharmaceutical industry (PharmaLetter-$)
• Russian drugmakers see delays in investment projects due to geopolitical tensions and sanctions (PharmaLetter-$)
• NHS could save £480m a year by cutting agency staff (PharmaTimes)
• UK research charity LifeArc appoints experienced leader Melanie Lee as new CEO (Pharmafile)

• Korean medtech companies to get a boost from Medtronic (Medical Design & Outsourcing)
• Gazyva, Imfinzi Launched Following Japan Listing, Entyvio In The Wings (SCRIP-$)

• J&J hip implants: Govt sets up new panel to decide final compensation for patients (Economic Times)
• Interim relief: J&J told to pay Rs 20 lakh to each recipient of faulty hip implant (Economic Times)
• I won't be silent anymore: Shivinder's charge against his brother in 6 points (Economic Times)

• ResApp announces strong results from Australian pediatric trial of respiratory diagnostic tool (mobihealthnews)
• Australia lists new ADHD and RA drugs on PBS (PharmaLetter-$)

• Improving drug safety in East Africa is aim of new project (EPR)